Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome.
Polycystic ovary syndrome (PCOS) is a common multifactorial endocrine disorder among women of childbearing age. PCOS has various and heterogeneous clinical features apart from its indefinite pathogenesis and mechanism. Clinical drugs for PCOS are multifarious because it only treats separate symptoms. Berberine is an isoquinoline plant alkaloid with numerous biological activities, and it was testified to improve some diseases related to PCOS in animal models and in humans. Systems pharmacology was utilized to predict the potential targets of berberine related to PCOS and the potential drug-drug interaction base on the disease network. In conclusion, berberine is a promising polypharmacological drug for treating PCOS, and for enhancing the efficacy of clinical drugs.
Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, 150040, Harbin, P.R. China.
Yu
Y
Wang
Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, 150040, Harbin, P.R. China.
Xin
X
Fu
Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, 150040, Harbin, P.R. China.
Jing
J
Xu
Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, 150040, Harbin, P.R. China.
Qiuhong
Q
Wang
Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, 150040, Harbin, P.R. China.
Haixue
H
Kuang
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001599:Berberine / Q000494:pharmacology*; D005260:Female; D057166:High-Throughput Screening Assays / Q000379:methods; D006801:Humans; D062105:Molecular Docking Simulation; D009363:Neoplasm Proteins / Q000737:chemistry / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011487:Protein Conformation / Q000187:drug effects*; D060066:Protein Interaction Maps / Q000187:drug effects*; D049490:Systems Biology
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D001599:Berberine